摘要
癌症仍然是有效治疗的致命疾病。虽然异常肿瘤微环境现在被广泛用于靶向化学疗法,但仍然不能安全有效地向肿瘤细胞递送药物。脂质体是有前途的可生物降解和生物相容的纳米载体,具有表面和内部修饰的潜在适应性,以及携带亲水性和疏水性药物的非凡能力。用肿瘤选择性配体和聚乙二醇化精心制造脂质体降低了免疫原性并增加了靶特异性。这篇综述着重于脂质体的关键发育方面,以利用增强的渗透性和保留(EPR)效应以及肿瘤选择性配体(如叶酸,转铁蛋白,多肽等)靶向癌细胞。此外,刺激响应智能脂质体(触发因素:pH,温度,还研究了酶,磁场,超声波和氧化还原电位等,以增强向肿瘤的药物递送。该综述总结了通过各种靶向手段靶向肿瘤的脂质体的进展。这种知识丰富的脂质体方法进展将为配方设计师和崭露头角的科学家提供新的见解,以设计针对癌症的脂质体。
关键词: 癌症,化疗,主动靶向,配体,抗癌剂,EPR效应,PEG化。
Current Molecular Medicine
Title:Advances in Tumor Targeted Liposomes
Volume: 18 Issue: 1
关键词: 癌症,化疗,主动靶向,配体,抗癌剂,EPR效应,PEG化。
摘要: Cancer remains a deadly disease for effective treatment. Although anomalous tumor microenvironment is now widely exploited for targeted chemotherapy, safe and efficacious drug delivery to tumor cells is not still warranted. Liposomes are promising biodegradable and biocompatible nanocarriers having potential amenability for surface and internal modifications, and extraordinary capability to carry both hydrophilic as well as hydrophobhic drugs. Meticulous fabrication of liposomes with tumor selective ligand(s) and PEGylation reduces immunogenicity and increase target-specificity. This review focuses on critical developmental aspects of liposomes to target cancer cells exploiting Enhanced Permeability and Retention (EPR) effect and tumor-selective ligands such as folate, transferrin, peptides etc. Moreover, stimuli-responsive smart liposomes (triggers: pH, temperature, enzymes, magnetic field, ultrasound, and redox potential etc.) are also investigated for enhancement of drug delivery to tumors. This review summarizes advances in tumor-targeted liposomes via various means of targeting. This knowledgeable assemblage of advances in liposomal approaches will render new insights to formulators and budding scientists to design cancer targeted liposomes.
Export Options
About this article
Cite this article as:
Advances in Tumor Targeted Liposomes, Current Molecular Medicine 2018; 18 (1) . https://dx.doi.org/10.2174/1566524018666180416101522
DOI https://dx.doi.org/10.2174/1566524018666180416101522 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ribonucleotide Reductase: A Mechanistic Portrait of Substrate Analogues Inhibitors
Current Medicinal Chemistry Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Potential Health Benefits of Berries
Current Nutrition & Food Science Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy for the Peripheral Nervous System: A Strategy to Repair the Injured Nerve?
Current Gene Therapy Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy Epigenetics and Adult Acute Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells
Current Signal Transduction Therapy “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Organic Synthesis Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species
Current Pharmaceutical Design Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Asthma, Allergy and Chemokines
Current Drug Targets